---
title: "CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289784441.md"
description: "The fifth individual administered with CER-1236, who did not show improvement with previous treatments, received a stem cell transplant. The company has commenced the third intended group in the continuous Phase 1 trial for hematologic malignancies."
datetime: "2026-06-15T12:16:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289784441.md)
  - [en](https://longbridge.com/en/news/289784441.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289784441.md)
generator: "portal-rs"
---

# CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

The fifth individual administered with CER-1236, who did not show improvement with previous treatments, received a stem cell transplant. The company has commenced the third intended group in the continuous Phase 1 trial for hematologic malignancies.

### Related Stocks

- [CERO.US](https://longbridge.com/en/quote/CERO.US.md)
- [CEROW.US](https://longbridge.com/en/quote/CEROW.US.md)

## Related News & Research

- [SRX Global buys senior secured debt in CERo Therapeutics Holdings](https://longbridge.com/en/news/297829391.md)
- [SRX Global buys senior secured debt in CERo Therapeutics Holdings](https://longbridge.com/en/news/297509635.md)
- [11:06 ETStem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research](https://longbridge.com/en/news/298223578.md)
- [Ocugen to Share Ophthalmic Gene Therapy Progress](https://longbridge.com/en/news/298375090.md)
- [10:03 ETDarkfin Labs, Founded by a Stem Cell Biologist, Brings Longevity Science to Ulta Beauty](https://longbridge.com/en/news/297798822.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**